Dr. Andy Chambers of Aspire Indiana Health announces a new clinical trial to test the effects of tezampanel (TZP) in reducing opioid withdrawal symptoms and helping patients with opioid use disorder (OUD) transition to full remission with injectable naltrexone. Learn more about this promising research!
#OpioidWithdrawal #ClinicalTrial #Tezampanel #OUD #AddictionRecovery #Naltrexone #OpioidCrisis #AspireIndiana